A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Inclusion Criteria:

• Participant must have histologically or cytologically confirmed, locally advanced ormetastatic, non-small cell lung cancer (NSCLC) that is not amenable to curativetherapy including surgical resection or chemoradiation. Additional Cohort specificdisease requirements include: Cohorts 1, 3, 3b, 5, 6 and 7: epidermal growth factorreceptor (EGFR) exon 19 deletion (Exon19del) or Exon 21 L858R mutation; Cohort 2:EGFR Exon 20ins mutation. Cohorts 1,5,and6: Participant should not have received anyprior systemic therapy for locally advanced or metastatic NSCLC. Cohort 2:Participant should not have received any prior systemic therapy for locally advancedor metastatic NSCLC. Cohorts 3and3b: Participant must have progressed on or afterosimertinib monotherapy as the most recent line of treatment. Osimertinib must havebeen administered as either the first-line treatment for locally advanced ormetastatic disease or in the second-line setting after prior treatment with first-or second-generation EGFR tyrosine kinase inhibitor (TKI) as a monotherapy. Cohort 4: Participants need to currently be on an amivantamab IV Q2W regimen (1,050 mg or 1,400 mg depending on weight) for at least 8 weeks, as part of standard of care, anexpanded access program, or as a rollover from a long-term extension, without anyamivantamab dose reduction. Cohort 7: Participants must have progressed on or afterthe combination of amivantamab and lazertinib as the most recent line of treatment.The combination of amivantamab and lazertinib must have been administered as thefirst-line treatment for locally advanced or metastatic disease. Cohort 2, 3, 3b,and 7 only: Squamous NSCLC are excluded. EGFR mutation must have been identified asdetermined by Food and Drug Administration (FDA) approved or other validated test ofeither circulating tumor deoxyribonucleic acid (ctDNA) or tumor tissue in a clinicallaboratory improvement amendments (CLIA) certified laboratory (sites in the Unitedstates [US]) or an accredited local laboratory (sites outside of the US). A copy ofthe initial test report documenting the EGFR mutation must be included in theparticipant records and a deidentified copy must also be submitted to the sponsor

• All cohorts except Cohort 4: Participants must have at least 1 measurable lesion,according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Ifthe only target lesion has been previously irradiated, it must show signs of diseaseprogression since radiation was completed If only 1 non-irradiated measurable lesionexists, which undergoes a biopsy and is acceptable as a target lesion, the baselinetumor assessment scans should be performed at least 14 days after the biopsy

• May have a prior or concurrent second malignancy (other than the disease understudy) which natural history or treatment is unlikely to interfere with any studyendpoints of safety or the efficacy of the study treatment(s)

• Have adequate organ (renal, hepatic, hematological, coagulation and cardiac)functions

• Participant must have eastern cooperative oncology group (ECOG) status of 0 or 1

• Cohort 6: Must be eligible for, and agree to comply with, the use of prophylacticanticoagulation with a direct oral anticoagulant or a low molecular weight heparinduring the first 4 months of study treatment

• A participant must agree not to donate eggs (ova, oocytes) or freeze for future usefor the purposes of assisted reproduction during the study and for a period of 6months after receiving the last dose of study treatment. Participants with childbearing potential should consider preservation of eggs prior to study treatment asanti-cancer treatments may impair fertility

Exclusion Criteria:

• Participant has a medical history of interstitial lung disease (ILD), including druginduced ILD or radiation pneumonitis

• Participant has a history of hypersensitivity to any excipients of theinvestigational products to be used in their enrollment cohort

• Participant has received a live or live attenuated vaccine within 3 months beforeCycle 1 Day 1. The seasonal influenza vaccine and non-live vaccines againstCoronavirus disease 19 (COVID-19) are not exclusionary

• For all cohorts (with regimens potentially including lazertinib): Participant iscurrently receiving medications or herbal supplements known to be potent Cytochrome (CYP3A4/5) inducers and is unable to stop use for an appropriate washout periodprior to Cycle 1 Day 1

• Other clinically active liver disease of infectious origin

• Participant has a history of clinically significant cardiovascular diseaseincluding, but not limited to: a) All cohorts: diagnosis of deep vein thrombosis orpulmonary embolism within 1 month prior to the first dose of study treatment(s), orany of the following within 6 months prior to the first dose of study treatment(s):myocardial infarction, unstable angina, stroke, transient ischemic attack,coronary/peripheral artery bypass graft, or any acute coronary syndrome. Clinicallynon-significant thrombosis, such as non-obstructive catheter-associated clots, arenot exclusionary; b) All cohorts (with regimens potentially including lazertinib):Participant has a significant genetic predisposition to venous thromboembolic events (VTE; such as Factor V Leiden); c) All cohorts (with regimens potentially includinglazertinib): Participant has a prior history of VTE and is not on appropriatetherapeutic anticoagulation as per NCCN or local guidelines; d) prolonged correctedQT interval by Fridericia (QTcF) interval greater than (>) 480 milliseconds (msec)or clinically significant cardiac arrhythmia or electrophysiologic disease (example,placement of implantable cardioverter defibrillator or atrial fibrillation withuncontrolled rate); e) uncontrolled (persistent) hypertension: systolic bloodpressure >160 millimeter(s) of mercury (mmHg); diastolic blood pressure >100 mmHg;f) Congestive heart failure defined as NYHA class III-IV or hospitalization forcongestive heart failure (CHF) (any New York Heart Association [NYHA] class) within 6 months of treatment initiation at Cycle 1/day 1 (C1D1); g) pericarditis/clinicallysignificant pericardial effusion; h) myocarditis; i) baseline left ventricularejection fraction (LVEF) below the institution's lower limit of normal at screening,as assessed by echocardiogram or multigated acquisition (MUGA) scan

• Participant has symptomatic brain metastases. A participant with asymptomatic orpreviously treated and stable brain metastases may participate in this study.Participants who have received definitive radiation or surgical treatment forsymptomatic or unstable brain metastases and have been clinically stable andasymptomatic for at least 2 weeks before Screening are eligible, provided they havebeen either off corticosteroid treatment or are receiving low-dose corticosteroidtreatment (less than or equal to [<=] 10 milligrams per day [mg/day] prednisone orequivalent) for at least 2 weeks prior to treatment allocation